Skip to search boxSkip to navigationSkip to main content

Preclinical Evidence for the Use of Oral Mesenchymal Stem Cell-Derived Extracellular Vesicles in Bone Regenerative Therapy: A Systematic Review

*Corresponding author for this work
  • Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO)
    ,
  • Instituto Biosanitario Ibs Granada
    ,
  • Pfizer-Universidad de Granada-Junta de Andalucía
    ,
  • ,
  • Maimonides Biomedical research Institute of Cordoba (IMIBIC)
    ,
Research Output:
Contribution to journal
Review article
Peer-review

Open access

Publication Information

Output type

Research Output:
Contribution to journal
Review article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 791-800 (10 pages)

Journal (Volume, Issue Number)

Stem cells translational medicine (Volume 12, Issue 12)

Publication milestones

  • Published - 12/2023

Publication status

Published - 12/2023

ISSN

2157-6564

Publication IDs

  • Scopus: 85180371602
  • PubMed: 37715961

Abstract

The development of extracellular vesicles (EVs) therapies has revolutionized personalized medicine, opening up new possibilities for treatment. EVs have emerged as a promising therapeutic tool within this field due to their crucial role in intercellular communication across various cell types and organisms. This systematic review aims to evaluate the therapeutic potential of oral mesenchymal stem cell (MSC)-derived EVs for bone regeneration, specifically focusing on findings from preclinical models. Sixteen articles meeting the inclusion criteria were selected following document analysis. The biological effects of oral MSC-derived EVs predominantly involve the upregulation of proteins associated with angiogenesis, and inflammation resolution, alongside the downregulation of proinflammatory cytokines. Moreover, these therapeutic agents have been found to contain a significant quantity of different molecules (proteins, lipids, DNA, microRNAs, etc) further contributing to their modulatory potential. The findings from this systematic review underscore that oral MSC-derived EVs, irrespective of their specific population, have the ability to enhance the osteogenic repair response in maxillary bone or periodontal defects. In summary, this systematic review highlights the promising potential of oral MSC-derived EVs for bone regeneration based on evidence from preclinical models. The comprehensive assessment of their biological effects and the presence of microRNAs underscores their therapeutic significance. These findings support the utilization of oral MSC-derived EVs in enhancing the osteogenic repair response in various maxillary bone or periodontal defects, providing insights into the mechanisms involved and potential therapeutic applications in the field of personalized medicine.

Funding Details

This article is based on work from COST Action Gene Editing for the treatment of Humans Diseases, CA21113, supported by COST (European Cooperation in Science and Technology). This research was supported in part by the Universidad Peruana de Ciencias Aplicadas, Lima, Perú (UPC-ExPost-2023-2). Incentives for Research of the. K. B. is funded through the PECART-0027-2020 (Consejería de Salud y Familias, Junta de Andalucía, Spain) and ProyExcel_00875 (Consejería de Transformación Económica, Industria, Conocimiento y Universidades, Junta de Andalucía, Spain). Additional funding for some authors includes that of the Research Group #CTS-1028 (MP-M and PG-M, Junta de Andalucía, Spain). All other funding was self-supported by the authors. Funding This research was supported in part by the Universidad Peruana de Ciencias Aplicadas, Lima, Perú (UPC-ExPost-2023-2). Incentives for Research of the. K. B. is funded through the PECART-0027-2020 (Consejería de Salud y Familias, Junta de Andalucía, Spain) and ProyExcel_00875 (Consejería de Transformación Económica, Industria, Conocimiento y Universidades, Junta de Andalucía, Spain). Additional funding for some authors includes that of the Research Group #CTS-1028 (MP-M and PG-M, Junta de Andalucía, Spain). All other funding was self-supported by the authors.
FundersFunding numbers
Universidad Peruana de Ciencias Aplicadas
UPC-ExPost-2023-2
Consejería de Transformación Económica, Industria, Conocimiento y Universidades
-1028
COST
CA21113
Consejería de Salud y Familias, Junta de Andalucía
ProyExcel_00875
Junta de Andalucía
-

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Captures
20
Citations
2
Mentions
1